Isomorphic Labs融资50亿美元推进AI制药
Isomorphic Labs完成50亿美元C轮融资,由Greenoaks与红杉资本领投,a16z作为新投资者加入,Alphabet及现有投资方也参与。公司计划推进IsoDDE并推动候选药物进入临床试验,但未披露最终估值,且自主研发药物尚未进入人体试验。Isomorphic Labs称IsoDDE在药物结合位点和对接位点预测上超越AlphaFold 3,相关报道未提供独立验证。
这笔融资凸显了资本市场对AI制药平台的大规模投入,而Isomorphic Labs的项目仍需通过临床试验验证。
Isomorphic Labs raises $5 billion in its second mega-round within six months
Maximilian Schreiner View the LinkedIn Profile of Maximilian Schreiner
Nov 17, 2026
Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.
The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.
The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.
#Isomorphic Labs#IsoDDE#Alphabet#Greenoaks#Sequoia Capital#Andreessen Horowitz#AlphaFold 3#Demis Hassabis